Therapeutic Equivalence (TE) Study of Propofol 2% MCT Fresenius (MCT=Medium-Chain Triglycerides) Compared With Diprivan® in Patients Undergoing Elective Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

February 28, 2014

Conditions
General AnesthesiaElective Surgery
Interventions
DRUG

Propofol

DRUG

Diprivan

Trial Locations (1)

33000

CHU de Bordeaux, Groupe Hospitalier Pellegrin, Bordeaux

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

Fresenius Kabi

INDUSTRY

NCT01856998 - Therapeutic Equivalence (TE) Study of Propofol 2% MCT Fresenius (MCT=Medium-Chain Triglycerides) Compared With Diprivan® in Patients Undergoing Elective Surgery | Biotech Hunter | Biotech Hunter